1. Home
  2. FIVE vs IONS Comparison

FIVE vs IONS Comparison

Compare FIVE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five Below Inc.

FIVE

Five Below Inc.

HOLD

Current Price

$229.42

Market Cap

12.0B

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$74.20

Market Cap

11.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIVE
IONS
Founded
2002
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
11.9B
IPO Year
2012
1996

Fundamental Metrics

Financial Performance
Metric
FIVE
IONS
Price
$229.42
$74.20
Analyst Decision
Buy
Strong Buy
Analyst Count
20
22
Target Price
$236.00
$93.14
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
06-03-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
40.65
21.71
EPS
6.47
N/A
Revenue
$4,764,147,000.00
N/A
Revenue This Year
$14.44
N/A
Revenue Next Year
$9.37
$77.99
P/E Ratio
$36.04
N/A
Revenue Growth
22.90
N/A
52 Week Low
$73.92
$30.01
52 Week High
$251.63
$86.74

Technical Indicators

Market Signals
Indicator
FIVE
IONS
Relative Strength Index (RSI) 49.61 49.35
Support Level $213.25 $69.85
Resistance Level $235.08 $74.42
Average True Range (ATR) 8.32 2.21
MACD -0.51 -0.15
Stochastic Oscillator 40.51 51.21

Price Performance

Historical Comparison
FIVE
IONS

About FIVE Five Below Inc.

Five Below Inc is a specialty value retailer offering a broad range of trend-right, high-quality products loved by the kid and the kid in all of customers. The Company's edited assortment of products includes select brands and licensed merchandise. The Company also sells its merchandise on the internet, through the Company's e-commerce website and mobile app, offering home delivery and the option to buy online and pick up in store. Additionally, the Company sells merchandise through on-demand third-party delivery services to enable its customers to shop online and receive convenient delivery. It derives revenue from sales of the Company's merchandise to customers.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: